Since its introduction in 1922 by Levaditi, acetarsone (stovarsol) has been given extensive clinical trial. It has been found useful in syphilis, yaws, malaria, amebic infections and several other diseases. It is a pentavalent arsenical compound with a high arsenic content and is administrable by mouth. It was introduced primarily as a spirillicidal remedy and it produces favorable clinical effects on syphilitic lesions, but experience has shown that it is not as effective as the trivalent arsphenamine compounds.
It is capable of producing untoward effects, among the most common being malaise, fever, edema, abdominal pain, jaundice, diarrhea, albuminuria, coryza, bronchitis and skin disorders.1
Among the dermal manifestations, urticaria and erythema have been most often noted. Less than a half dozen cases of exfoliative dermatitis due to acetarsone have been reported, and therefore a brief report of a case of this nature seems warranted. An additional reason for recording the